RNXT
RenovoRx, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
1.31
▼ 0.01 (0.76%)
MARKET · —
Price
Open
1.32
Prev close
1.32
Day high
1.33
Day low
1.25
Volume
233.06K
Market cap
$59.57M
P/E (TTM)
—
52W range
0.70 – 1.51
Trailing performance
Returnvs SPY
1W
-5.71%
-4.3%
1M
+54.39%
+50.7%
3M
+49.66%
+46.6%
6M
+44.58%
+33.5%
YTD
+57.14%
+44.9%
1Y
+51.72%
+31.7%
3Y
-22.81%
-97.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$59.57M
Enterprise value$50.48M
Revenue (TTM)$1.98M
Gross profit$1.67M
EBITDA$-13.03M
Net income$-12.29M
EPS (TTM)$-0.31
Free cash flow$-6.65M
Total cash$9.48M
Total debt$390.00K
Book value / share$0.20
Shares outstanding45.13M
Float39.20M
Short % of float0.65%
Dividend yield—
Beta (5Y)0.99
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.52
PEG ratio—
Price / sales—
Price / book6.63
EV / revenue25.55
EV / EBITDA-3.87
Gross margin84.41%
Operating margin-368.43%
Profit margin0.00%
Return on equity-125.23%
Return on assets-64.90%
Debt / equity4.34
Current ratio5.74
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.12M | $43.00K | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$11.17M | -$8.81M | -$10.23M | -$9.89M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$11.17M | -$8.81M | -$10.23M | -$9.89M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | -0.05 | +33.3% |
| Mar 2026 | -0.08 | -0.08 | -4.3% |
| Dec 2025 | -0.08 | -0.08 | 0.0% |
| Sep 2025 | -0.08 | -0.08 | 0.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.03 | 1 | $952.00K | +257.9% |
| Next quarter | -0.03 | 1 | $1.31M | +450.8% |
| Current year | -0.21 | 1 | $3.65M | +224.6% |
| Next year | -0.16 | 2 | $10.06M | +175.9% |
Analyst targets & ownership
Mean target$7.00
High target$14.00
Low target$3.00
Implied upside434.35%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders3.42%
Held by institutions20.38%
Institutions holding30
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.54M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 19, 26 | VOLL MARK Chief Financial Officer |
BUY | 25.00K | $19.69K | Direct |
| Apr 2, 26 | VOLL MARK Chief Financial Officer |
STOCK | 80.00K | $0 | Direct |
| Mar 25, 26 | VOLL MARK Chief Financial Officer |
STOCK | 12.38K | $0 | Direct |
| Mar 20, 26 | VOLL MARK Chief Financial Officer |
BUY | 97.20K | $97.20K | Indirect |
| Mar 20, 26 | MARTON LAURENCE Director |
BUY | 9.72K | $9.72K | Indirect |
| Mar 20, 26 | BAGAI SHAUN R. Chief Executive Officer |
BUY | 24.30K | $24.30K | Indirect |
| Jan 21, 26 | AGAH RAMTIN M.D. Officer and Director |
BUY | 10.00K | $9.97K | Direct |
| Dec 31, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 9.79K | $8.42K | Direct |
| Dec 30, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 205 | $169 | Direct |
| Dec 18, 25 | BAGAI SHAUN R. Chief Executive Officer |
BUY | 5.00K | $4.51K | Direct |
| Dec 17, 25 | BAGAI SHAUN R. Chief Executive Officer |
BUY | 5.00K | $4.26K | Direct |
| Dec 16, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 12.00K | $10.20K | Direct |
| Dec 5, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 10.00K | $9.60K | Direct |
| Nov 24, 25 | AGAH RAMTIN M.D. Officer and Director |
BUY | 22.00K | $17.60K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGAH RAMTIN M.D. |
Officer and Director | 798.46K | Purchase |
BAGAI SHAUN R. |
Chief Executive Officer | — | Purchase |
KOCAK RONALD B. CPA |
Officer | 12.60K | Purchase |
MARTON LAURENCE |
Director | — | Purchase |
VOLL MARK |
Chief Financial Officer | 239.58K | Purchase |
Moving averages & technicals
SMA 10
1.24
+5.52% from price
SMA 20
1.13
+17.26% from price
SMA 50
0.99
+33.02% from price
SMA 100
0.95
+37.75% from price
SMA 200
0.95
+39.58% from price
EMA 12
1.22
+7.51% from price
EMA 26
1.12
+17.01% from price
EMA 50
1.04
+25.83% from price
RSI (14)
64.5
Neutral
MACD (12,26,9)
0.10
Hist 0.02
ATR (14)
0.13
9.72% of price
Realised vol 30D
93.9%
Annualised
Bollinger upper
1.41
20, 2σ
Bollinger lower
0.84
20, 2σ
50 / 200 cross
Golden
0.99 vs 0.95
Trend bias
Above 200
+39.58%
Risk profile
Beta vs SPY
1.43
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
93.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-45.3%
Peak to trough
Max drawdown 5Y
-96.3%
Peak to trough
ATR 14
0.13
9.72% of price
Beta (reported)
0.99
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire · 1d ago
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
GlobeNewswire · 2d ago
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
MarketBeat · 6d ago
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
GuruFocus.com · 10d ago
RenovoRx, Inc. Q2 2026 Earnings Call Summary
Moby · 10d ago
RenovoRx Q2 Earnings Call Highlights
MarketBeat · 10d ago
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 10d ago
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
GlobeNewswire · 10d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.